VectorY Therapeutics

Alexander Vos, CEO

Amsterdam, Netherlands


Virtual Presentation

VectorY Therapeutics is combining the power of gene therapy technology and antibodies to develop new therapies for neurodegenerative and muscle diseases. Founded in October 2020, and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics based on a novel AAV gene therapy platform, antibody- and RNA-based targeted degradation technologies, and proprietary manufacturing technology. VectorY develops proprietary and partnered programs. Product candidates are based on new technologies that will enable the next generation of highly scalable manufacturing processes.

By using this website you agree to accept our Privacy Policy and Terms & Conditions